Corporate Medical Policy

Ultraviolet Light Therapy in the Home Setting (UVB)

**File Name:** ultraviolet_light_therapy_in_the_home

**Origination:** 3/1996

**Last CAP Review:** 11/2017

**Next CAP Review:** 11/2018

**Last Review:** 11/2017

**Description of Procedure or Service**

Home ultraviolet light box/cabinets or ultraviolet lamps are durable medical equipment that typically contain multiple fluorescent lights that emit high intensity, ultraviolet light (UVB). These boxes/lamps have been used for various reasons including treatment of psoriasis, eczema, photodermatoses, pruritus, pityriasis, lichen planus, parapsoriasis, and pruritic eruptions of HIV infection, vitiligo, cutaneous T-cell lymphoma (CTCL)/mycosis fungoides and acne.

This policy addresses light therapy for home use only. Please see BCBSNC policy “Light Therapy for Dermatologic Conditions” for therapy provided in the medical office setting.

**Related Policies:**

Durable Medical Equipment

Light Therapy for Dermatologic Conditions

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.***

**Policy**

BCBSNC will provide coverage for ultraviolet light therapy in the home setting when it is determined to be medically necessary because the medical criteria and guidelines shown below are met.

**Benefits Application**

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

**When Ultraviolet Light Therapy in the Home Setting is covered**

Ultraviolet Light Therapy in the Home is considered medically necessary when all of the following criteria are met:

- Patient has a diagnosis of extensive and refractory psoriasis, atopic dermatitis, eczema, cutaneous T-cell lymphoma (CTCL)/mycosis fungoides, or hepatic or renal failure associated pruritus.

- Extensive and refractory involvement of the palms or soles with psoriasis would be considered sufficient for coverage.
Ultraviolet Light Therapy in the Home Setting (UVB)

- Initially, the patient requires UV light treatments at least 3 times per week.

**When Ultraviolet Light Therapy in the Home Setting is not covered**

Ultraviolet light therapy in the home is considered not medically necessary when:

- The patient does not meet all of the qualifying clinical diagnoses or requirements;
- It is being prescribed solely for the member’s convenience;
- It is for cosmetic purposes such as tanning.

**Policy Guidelines**

Extensive disease is defined as more than 5% of the body surface area affected.

Refractory disease is defined as failure of adequate trials of topical regimens such as steroids or coal/tar preparations.

Koek and colleagues conducted a randomized controlled single-blind trial comparing office-based UVB treatment to home therapy for individuals with plaque or guttate psoriasis. (PLUTO) This study involved 196 subjects who were evaluated through the initial therapy, with the first 105 subjects followed for an additional 12 months post-treatment. The authors reported that both treatments provided significant improvement from baseline, with home therapy being non-inferior to office based treatment as measured by the psoriasis area and severity index (PASI) and the self administered psoriasis area and severity index (SAPASI). No differences between groups were reported with regard to total cumulative radiation dose or short term side effects.

A second review of the PLUTO trial assessed the costs and cost effectiveness of UVB home light therapy compared to outpatient UVB therapy for psoriasis. The results showed that home UVB phototherapy is not more expensive than therapy received in the outpatient setting and patients expressed a preference for home treatment.

According to the American Academy of Dermatology Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis, home UVB therapy is a safe and effective treatment option for many patients; however, patients must be educated as to the potential long-term side effects of UVB – including an increased risk of skin cancer and premature aging – and protect their eyes by using goggles to decrease the risk of UVB-related cataracts that could form from prolonged exposure.

Prior to providing a prescription for home UVB therapy, patients should demonstrate improvement with initial UVB treatments in the provider’s office or symptom improvement with sun exposure.

**Billing/Coding/Physician Documentation Information**

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

*Applicable codes: E0691, E0692, E0693, E0694, A4633*
Ultraviolet Light Therapy in the Home Setting (UVB)

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources

Plan Consultant - 3/96

Plan Medical Director - 3/99


Specialty Matched Consultant Advisory Panel review 2/2013


Medical Director review 4/2012

Specialty Matched Consultant Advisory Panel review 2/2013

Ultraviolet Light Therapy in the Home Setting (UVB)


Medical Director review 6/2013


Specialty Matched Consultant Advisory Panel review 1/2014

Medical Director review 1/2014

Specialty Matched Consultant Advisory Panel review 1/2015

Medical Director review 1/2015

Specialty Matched Consultant Advisory Panel review 1/2016

Medical Director review 1/2016

Policy Implementation/Update Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3/96</td>
<td>Original policy issued.</td>
</tr>
<tr>
<td>3/97</td>
<td>Reaffirmed</td>
</tr>
<tr>
<td>3/99</td>
<td>Policy changed for compliance issues based on Plan Medical Director recommendations.</td>
</tr>
<tr>
<td>5/99</td>
<td>Reformatted. Medical term definitions added.</td>
</tr>
<tr>
<td>10/99</td>
<td>Medical Policy Advisory Group</td>
</tr>
<tr>
<td>3/01</td>
<td>System coding changes. Name of policy changed from Home Ultraviolet Light Box to Ultraviolet Light Box Therapy in the Home. Added atopic dermatitis, eczema, pruritus, or cutaneous T-cell lymphoma (CTCL)/mycosis fungoides as covered indications. Disease must be refractory to conservative measures. Patient must have shown improvement with light box therapy in the physician’s office, and patient must be capable of operating the light box and staying within the prescribed periods of exposure. Statement added indicating the harmful effects of ultraviolet light box therapy.</td>
</tr>
<tr>
<td>4/02</td>
<td>Reformatted policy for clarification. Billing and coding guidelines changed to indicate documentation needs for covered diagnoses. No changes to Billing/Coding section.</td>
</tr>
</tbody>
</table>
Ultraviolet Light Therapy in the Home Setting (UVB)

section; first bullet: "Severe and refractory involvement of the palms or soles with any of the listed conditions would be considered extensive." Reference sources added.

5/21/07 Under When Covered section, removed bullet #4 re: "Member is not capable of traveling......" Under Billing/Coding section, removed #3. Reference source added. (pmo)

8/13/07 Medical Policy changed to Evidence Based Guideline (Active guideline, no longer scheduled for routine literature review). (pmo)

6/22/10 Policy Guideline Number(s) removed (amw)

9/28/10 Added diagnosis code 709.1 to “Billing/Coding” section (mco)

2/15/11 Deleted diagnosis code 709.1 and added diagnosis code 709.01 to “Billing/Coding” section. (mco)

5/15/12 Policy archived. Indications for ultraviolet light box therapy in the home are addressed in the policy titled, “Light Therapy for Dermatologic Conditions.” Medical Director review 4/2012. (mco)

7/30/13 Policy returned to active status and changed from Evidence Based Guideline to Corporate Medical Policy. Policy re-titled from “Ultraviolet Light Box Therapy in the Home Setting” to “Ultraviolet Light Therapy in the Home Setting.” Policy Guidelines updated. References updated. Medical Director review 6/2013. (mco)


1/27/17 Specialty Matched Consultant Advisory Panel review 11/30/2016. No change to policy statement. (an)

12/15/17 Specialty Matched Consultant Advisory Panel review 11/29/2017. No change to policy statement. (an)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.